Summary of immunohistochemical results
. | NKTCL (n = 16) . | NKTCL cell lines (n = 2) . | PTCL, NOS (n = 17) . |
---|---|---|---|
Clusterin | 0/4 (0%) | 0/1 | ND |
E-cadherin | 0/4 (0%) | ND | ND |
Cyclin D1 | 0/4 (0%) | ND | ND |
EGFR | 0/4 (0%) | ND | ND |
CD163 | 0/4 (0%) | 0/2 | ND |
EBI3 | 9/12 (75%) | 2/2 | 1/13 (8%) |
VCAM1 | 4/13 (31%) | 0/2 | 0/7 (0%) |
Granzyme H | 16/16 (100%) | 2/2 | 2/16 (13%) |
pSTAT3 | 13/14 (93%) | 2/2* | 2/17 (12%) |
pAKT | 9/9 (100%) | NE | 0/16 (0%) |
VEGFA | 9/9 (100%) | 2/2 | 5/13 (38%) |
VEGFR2 | 4/5 (80%) | 2/2† | ND |
PDGFRα | 11/13 (85%) | 1/1 | 10/10 (100%) |
pPDGFRα | 13/13 (100%) | ND | 7/8 (88%) |
RelA | 5/6 (83%)‡ | 2/2‡ | ND |
RelB | 0/6 (0%) | ND | ND |
cRel | 4/5 (80%)§ | 0/2 | ND |
Beta-catenin | 0/8 (0%) | ND | ND |
. | NKTCL (n = 16) . | NKTCL cell lines (n = 2) . | PTCL, NOS (n = 17) . |
---|---|---|---|
Clusterin | 0/4 (0%) | 0/1 | ND |
E-cadherin | 0/4 (0%) | ND | ND |
Cyclin D1 | 0/4 (0%) | ND | ND |
EGFR | 0/4 (0%) | ND | ND |
CD163 | 0/4 (0%) | 0/2 | ND |
EBI3 | 9/12 (75%) | 2/2 | 1/13 (8%) |
VCAM1 | 4/13 (31%) | 0/2 | 0/7 (0%) |
Granzyme H | 16/16 (100%) | 2/2 | 2/16 (13%) |
pSTAT3 | 13/14 (93%) | 2/2* | 2/17 (12%) |
pAKT | 9/9 (100%) | NE | 0/16 (0%) |
VEGFA | 9/9 (100%) | 2/2 | 5/13 (38%) |
VEGFR2 | 4/5 (80%) | 2/2† | ND |
PDGFRα | 11/13 (85%) | 1/1 | 10/10 (100%) |
pPDGFRα | 13/13 (100%) | ND | 7/8 (88%) |
RelA | 5/6 (83%)‡ | 2/2‡ | ND |
RelB | 0/6 (0%) | ND | ND |
cRel | 4/5 (80%)§ | 0/2 | ND |
Beta-catenin | 0/8 (0%) | ND | ND |
Results refer to expression in neoplastic cells.
ND indicates not done; and NE, nonevaluable.
Phosphorylated STAT3 stained most MEC04 cells, but only a minority of SNK6 cells.
Performed by flow cytometric immunophenotyping.
Cytoplasmic and nuclear staining of neoplastic cells.
Cytoplasmic staining of most neoplastic cells.